EN DE
Watch Elutia Inc. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Elutia Inc. (ELUT) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Elutia Inc. stock $2.65, price $0.9, upside +194.4%, quality 48 out of 100. Rating: strongly undervalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US05479K1060

EI Elutia Inc. logo Thin data Nov 22, 2026

Elutia Inc.

ELUT · US

Cheap (66% below fair value) and rising price, but weak company: meets 2 of 3 rules.

Follow free in the weekly email
Fair value $2.65 · Strongly undervalued 
Rising price (uptrend) 
Even on cautious assumptions the value is 121% above the price ($1.99). 
Quality 48/100 
Mixed Growth (revenue 5y −10.7 %/yr in USD) 
Moderate debt 
Mixed vs. peers (4/8) 
Negative free cash flow 
Narrow moat 40/100 · thin data
Thin data 
Watch Elutia Inc. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$9.23 $0.505 Fair Value $2.65 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.

How to read this chart

60‑month range $0.505 – $9.23 · fair‑value band $1.99 – $3.31 · the $0.9 price screens below the $2.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 22, 2026.

Follow Elutia in your weekly email

Every Wednesday you see whether Elutia is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.

Show moreShow less

Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.

It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery.

In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature.

The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023.

Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Stock analysis

Elutia Inc. (ELUT) currently trades at $0.9, while our model-based Fair Value estimate is $2.65, implying the stock looks roughly 66% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $19.98 per share, and 7 of the 8 models we run sit above the $0.9 price.

Bear case: the Asset-Based group reads lowest at $0.48, and 1 of the 8 models stay below the price. Data coverage for this calculation is low.

Scenario range: $1.99 (bear) to $3.31 (bull), the price of $0.9 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.

Elutia Inc. reported revenue of $12.3M in FY2025 versus $47.4M in FY2021, a compound −28.6%/yr. Reported net income was $53.4M in FY2025.

Key figures

Market cap $39.3M Micro · P/S ratio 2.94 · EPS (TTM) $-0.68 · Return on assets (EBIT) −56.8% (5-year average) · Operating margin −166% · Revenue (TTM) $13.6M · Revenue growth (quarter YoY) +20.4% · Free cash flow −$46.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 78% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 194%, ELUT screens cheaper than that median.

Fair Value models

Bear $1.99 Fair Value $2.65 Bull $3.31
Price $0.9 · Upside +194.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $7.44 $10.04 $14.70 77
Residual Income $1.77 $1.96 $2.98 70
Graham-Dodd $8.18 $9.99 $11.24 67
All 8 models by family
DCF Models
Owner Earnings $7.44 $10.04 $14.70 77
Earnings-Based
Graham-Dodd $8.18 $9.99 $11.24 67
Multiples
P/E Multiple $19.84 $26.45 $33.06 63
P/S Multiple $0.7300 $0.9700 $1.21 58
P/B Multiple $1.99 $2.65 $3.31 55
Asset-Based
NCAV (Graham) $0.3100 $0.4800 $0.6000 54
Economic Profit
Residual Income $1.77 $1.96 $2.98 70
Growth Earnings
Growth-Adj P/E $13.98 $19.98 $25.97 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 65
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 61
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyKevin RakinDirector, 10% owner70,000 shares at $1.06$74,200Jan 30, 2026
  • BuyGuido J NeelsDirector2× since Jan 28, 2026: 50,000 shares, avg. $1.05$52,600Jan 30, 2026
  • BuyHighCape Partners GP II, LLC10% owner50,000 shares at $0.5200$26,000Dec 17, 2025
  • BuyMatthew FergusonCHIEF FINANCIAL OFFICER2× since Dec 1, 2025: 70,000 shares, avg. $0.5487$38,410Dec 17, 2025
  • BuyC Randal MillsPRESIDENT AND CEO, Director2× since Nov 24, 2025: 8,000 shares, avg. $0.5663$4,530Dec 17, 2025
  • BuyBrigid MakesDirector25,000 shares at $0.5200$13,000Dec 17, 2025
  • BuyDavid ColpmanDirector12,500 shares at $0.5100$6,375Dec 17, 2025

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.7%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−31.9% (2020) → −149.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch ELUT, get fair value alerts →

Compare Elutia Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 399 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside +194.4% · Top 25%
Profitability
Return on assets 85.6% · Top 25%
Operating margin (12 months) −166.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 20.4% · Above median
Balance sheet
Debt / equity 0.82× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.42× · Cheaper than median
P/S (12 months) 2.89× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 19
FUTURE (revenue growth)100 · sector 41
PAST (return on equity)0 · sector 2
HEALTH (low debt)59 · sector 97
DIVIDEND (yield)0 · sector 35

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $310.00 $341.00 +10% vs ELUT
Boston Scientific Corporation BSX $41.98 $46.18 +10% vs ELUT
DexCom, Inc DXCM $79.32 $87.25 +10% vs ELUT
STERIS plc STE $255.76 $281.34 +10% vs ELUT
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥183.81 ¥197.34 +7% vs ELUT
GE HealthCare Technologies Inc GEHC $80.64 $69.92 −13% vs ELUT
Edwards Lifesciences Corporation EW $101.85 $81.94 −20% vs ELUT
Medtronic plc MDT $99.94 $74.89 −25% vs ELUT
Abbott Laboratories, ABT $103.00 $75.28 −27% vs ELUT
Koninklijke Philips N.V PHIA €26.39 €15.23 −42% vs ELUT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elutia Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Elutia Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ELUT

Frequently asked questions

Is Elutia Inc. (ELUT) overvalued or undervalued?
As of Nov 22, 2026, our model estimates a fair value of $2.65 versus a price of $0.9, about +194% upside (undervalued).
What is the fair value of ELUT?
Our model-based fair value for Elutia Inc. is $2.65 (as of Nov 22, 2026), built from audited fundamentals. The current price: $0.9.
What is the quality score of ELUT?
Elutia Inc. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elutia Inc. (ELUT)?
We do not set a price target; the yardstick is the fair value of $2.65 (as of Nov 22, 2026) from 8 valuation models. Cautious scenario $1.99, optimistic scenario $3.31. It is a calculation from audited fundamentals, not an analyst target.
What is the Elutia Inc. stock forecast for 2026?
Our models put fair value at $2.65, about +194% upside versus a price of $0.9 (undervalued). Cautious scenario $1.99, optimistic scenario $3.31. The calculation is refreshed regularly with new filings.
What is the revenue of Elutia Inc. (ELUT)?
Elutia Inc. reported trailing-twelve-month revenue of about $13.6M (latest available figure, as of Nov 22, 2026).
What is the intrinsic value of Elutia Inc. (ELUT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elutia Inc. it is $2.65 per share (as of Nov 22, 2026), against a price of $0.9. It is the blended result of 8 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Elutia Inc. stock overvalued or undervalued in 2026?
As of Nov 22, 2026, ELUT trades below its calculated fair value: price $0.9, fair value $2.65, a gap of about +194% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELUT?
No. The price is what the market pays today ($0.9); the fair value is what the company's own numbers justify ($2.65). For Elutia Inc. the two are $1.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elutia Inc. worth?
The market values Elutia Inc. at about $39.3M (market capitalisation, as of Nov 22, 2026). Per share that is $0.9; our models calculate a fair value of $2.65 per share.
What do the bullish and bearish scenarios say about ELUT?
Our models span a range for Elutia Inc.: cautious scenario $1.99, base $2.65, optimistic $3.31 per share (as of Nov 22, 2026, price $0.9). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Elutia Inc. (ELUT)?
Balance-sheet figures for Elutia Inc. (as of Nov 22, 2026): debt of 0.82 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is ELUT from its 52-week high?
Elutia Inc. trades at $0.9, about 26% below its 52-week high of $1.22 and 78% above the low of $0.505 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $2.65 is for.
Which stocks are comparable to Elutia Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elutia Inc. stock attractive at the current price?
The data as of Nov 22, 2026: price $0.9, calculated fair value $2.65 (+194%), Quality Score 48/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELUT calculated?
We run Elutia Inc. through 8 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $2.65 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Elutia Inc. currently trades 66% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elutia Inc. (ELUT)?
The closing price on Nov 20, 2026 was $0.9. Our model-based fair value is $2.65, about +194% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elutia Inc. right now?
The large discount to fair value meets weak quality (48/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($1.99). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Elutia Inc.

How large is the market capitalisation of Elutia Inc. (ELUT)?
The market capitalisation of Elutia Inc. is $39.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elutia Inc. (ELUT)?
The price-to-sales ratio of Elutia Inc. is 2.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elutia Inc. (ELUT)?
Earnings per share at Elutia Inc. are $-0.68. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Elutia Inc. (ELUT)?
On an EBIT basis the return on assets of Elutia Inc. is −56.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elutia Inc. (ELUT)?
The operating margin of Elutia Inc. is −166% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elutia Inc. (ELUT)?
Revenue at Elutia Inc. is growing 20.4% in the last quarter versus the same quarter a year earlier (3y avg −19.9%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How much free cash flow does Elutia Inc. (ELUT) generate?
The free cash flow of Elutia Inc. is −$46.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Elutia Inc. (ELUT) hold?
Elutia Inc. holds more cash than debt, $25.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Elutia Inc. in the live analysis

One click puts Elutia Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.